CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,300 target
Drug / intervention
cisplatin +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002823
NCT00002823Phase 3Completed

A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER

Gustave Roussy, Cancer Campus, Grand Paris·interventional·Posted Mar 11, 2004·Updated Mar 28, 2013

In Brief

A Phase 3 clinical trial evaluating cisplatin, etoposide, and 4 other interventions for Lung Cancer. Completed, enrolled 3,300 participants across 123 sites in 29 countries.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy following surgery with that of surgery alone in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesArgentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Egypt, Federal Republic of Yugoslavia, France, Greece, Israel, Italy, Japan, Lithuania, Morocco, North Macedonia, Norway, Philippines, Poland, Portugal, Slovenia, South Africa, Spain, Sweden, Switzerland, Tunisia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 11, 2004
Enrollment StartFeb 1, 1995
Primary CompletionJan 1, 2001
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 22.3 years ago

Interventions

cisplatindrug

etoposidedrug

vinblastine sulfatedrug

vindesinedrug

vinorelbine tartratedrug

radiation therapyradiation